Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin for prevention of ventilator-associated pneumonia
IRCT20220702055337N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amikacin in ventilator-associated pneumonia (VAP) and pneumonia, sponsored by Arak University of Medical Sciences. Primary endpoint: Incidence of ventilator-associated pneumonia. Started Sep 2022; status: completed.
02
Drugs
amikacin
03
Conditions
ventilator-associated pneumonia (VAP)pneumonia
Beyond the preview
Go deeper on IRCT20220702055337N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220702055337N1.